June 2019 - Volume 3 - Issue - Contributor Index

Author:
R, C.
Author:
Raab, M. S.

HIGH DOSE MELPHALAN (200MG/M2) AND AUTOLOGOUS TRANSPLANTATION IN NEWLY-DIAGNOSED MULTIPLE MYELOMA UP TO THE AGE OF 70 YEARS: A SUBGROUP ANALYSIS FROM THE PHASE III GMMG-MM5 TRIAL: PF597

Mai, E. K.; Miah, K.; Merz, M.; More

HemaSphere. 3:251-252, June 2019.

ELOTUZUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: EFFICACY RESULTS AFTER ADDITIONAL FOLLOW-UP OF THE PHASE 2, RANDOMIZED ELOQUENT-3 STUDY: PS1370

Dimopoulos, M.; Dytfeld, D.; Grosicki, S.; More

HemaSphere. 3:626-627, June 2019.

Author:
Raaijmakers, M.
Author:
Raanani, P.
Author:
Rab, M.
Author:
Rabe, K.
Author:
Rabe, K. G.
Author:
Rabian, F.
Author:
Rabin, N.

BORTEZOMIB-HIGH DOSE METHYLPREDNISOLONE OFFERS IMPROVED HAEMATOLOGICAL RESPONSES AND OVERALL SURVIVAL COMPARED TO BORTEZOMIB-DEXAMETHASONE IN SYSTEMIC LIGHT CHAIN AMYLOIDOSIS: PB2127

Mahmood, A. S.; Sachchithanantham, S.; Harrison, S.; More

HemaSphere. 3:958, June 2019.

Author:
Racil, Z.

CLINICAL IMPLICATIONS OF AZOLE-RESISTANT VERSUS AZOLE-SUSCEPTIBLE INVASIVE ASPERGILLOSIS IN HEMATOLOGICAL MALIGNANCY (CLARITY) - A MULTICENTER STUDY: PS1283

Cornely, O. A.; Seidel, D.; Arenz, D.; More

HemaSphere. 3:587, June 2019.

Author:
Rácil, Z.

CHROMOSOMAL ABNORMALITIES DETERMINE OUTCOME IN NPM1MUT/FLT3-ITDNEG/LOW ACUTE MYELOID LEUKEMIA: S1614

Angenendt, L.; Röllig, C.; Montesinos, P.; More

HemaSphere. 3:744-745, June 2019.

Author:
Rad, R.
Author:
Raddadi, R.
Author:
Radeski, D.
Author:
Radford, J.

FRONTLINE BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY FOR STAGE 3/4 CLASSICAL HODGKIN LYMPHOMA: 3-YEAR UPDATE OF THE ECHELON-1 STUDY: S820

Gallamini, A.; Straus, D.; Dlugosz-Danecka, M.; More

HemaSphere. 3:362-363, June 2019.

B-CELL PROLYMPHOCYTIC LEUKEMIA (B-PLL) AND PROLYMPHOCYTOID MANTLE CELL LYMPHOMA (PMCL) (MORE THAN 55% OF PROLYMPHOCYTES) ARE CLOSED BUT DISTINCT ENTITIES. ON BEHALF GFCH AND FILO GROUPS: PB1868

Chapiro, E.; Diop, K.; Dessen, P.; More

HemaSphere. 3:851-852, June 2019.

Author:
Radia, D.

AVAPRITINIB, A POTENT AND SELECTIVE INHIBITOR OF KIT D816V, INDUCES COMPLETE AND DURABLE RESPONSES IN PATIENTS (PTS) WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM): S830

Radia, D.; Deininger, M. W.; Gotlib, J.; More

HemaSphere. 3:368, June 2019.

Author:
Radich, J.
Author:
Radich, J. P.

DURABILITY AND IMPACT ON QUALITY OF LIFE OF TREATMENT-FREE REMISSION (TFR) IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) AFTER STOPPING FRONTLINE (1L) NILOTINIB: ENESTFREEDOM 192-WK RESULTS: PF409

Ross, D. M.; Masszi, T.; Casares, Gómez M.T.; More

HemaSphere. 3:157, June 2019.

Author:
Radinoff, A.
Author:
Radman, I.
Author:
Radman, M.

LOWER SERUM LEVELS OF ZINC AND MAGNESIUM ARE ASSOCIATED WITH WORSE ORAL CGVHD AND DYSGEUSIA IN CGVHD PATIENTS: PF773

Mravak-Stipetic, M.; Radman, M.; Desnica, L.; More

HemaSphere. 3:341, June 2019.

Author:
Radova, L.
Author:
Radová, L.
Author:
Radtke, F.
Author:
Radu, E.
Author:
Radujkovic, A.
Author:
Radzhabova, A.

THE ROLE OF FLT3 MUTATIONS IN ACUTE MYELOID LEUKEMIA: THE EFFECT ON THE COURSE OF THE DISEASE AND THE RESULTS OF THERAPY: PB1744

Radzhabova, A.; Voloshin, S.; Martynkevich, I.; More

HemaSphere. 3:802, June 2019.

Author:
raffat, D.
Author:
Rafferty, B.

ELOTUZUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: EFFICACY RESULTS AFTER ADDITIONAL FOLLOW-UP OF THE PHASE 2, RANDOMIZED ELOQUENT-3 STUDY: PS1370

Dimopoulos, M.; Dytfeld, D.; Grosicki, S.; More

HemaSphere. 3:626-627, June 2019.

Author:
Raffini, M.

LONG TERM OUTCOME OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS: THE ROLE OF MINIMAL RESIDUAL DISEASE: PB2324

Paolini, S.; Romani, L.; Ottaviani, E.; More

HemaSphere. 3:1036, June 2019.

Author:
Raffoux, E.

MITOCHONDRIAL PRIMING OF BLASTS, BUT NOT LSC, PREDICTS SURVIVAL IN OLDER AML PATIENTS TREATED INTENSIVELY INDEPENDENTLY OF ONCOGENETICS: A STUDY ON THE ALFA 1200 TRIAL: PF211

Dal Bello, R.; Adès, L.; Braun, T.; More

HemaSphere. 3:57, June 2019.

A RANDOMIZED, OPEN-LABEL, PHASE II STUDY OF SELINEXOR VERSUS PHYSICIAN'S CHOICE (PC) IN OLDER PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML): PF261

Sweet, K.; Blum, W.; Donner, H.; More

HemaSphere. 3:82-83, June 2019.

MUTANT IDH1 INHIBITOR IVOSIDENIB (AG-120) IN COMBINATION WITH AZACITIDINE FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: PS1023

DiNardo, C. D.; Stein, A. S.; Stein, E. M.; More

HemaSphere. 3:460-461, June 2019.

Author:
Rafiq, S.
Author:
Ragab, I.
Author:
Ragaini, S.

LONG TERM OUTCOME OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS: THE ROLE OF MINIMAL RESIDUAL DISEASE: PB2324

Paolini, S.; Romani, L.; Ottaviani, E.; More

HemaSphere. 3:1036, June 2019.

Author:
Raghavan, M.
Author:
Raghoo, R.

MOLECULAR PROFILING OF PRIMARY BONE LYMPHOMA'S REVEALS FREQUENT MUTATIONS IN EZH2 AND OTHER EPIGENETIC GENES: IMPLICATIONS FOR TARGETED TREATMENT: PF519

Ibramoglu, Suleiman M.; de Groen, R. A.; van Eijk, R.; More

HemaSphere. 3:212, June 2019.

Author:
Raheja, P.
Author:
Rahman, J.
Author:
Rahmanuddin, S.
Author:
Rahn, K.
Author:
Rai, R. Ph. D
Author:
Raia, M.
Author:
Rainford, Z.
Author:
Raiola, A. M.
Author:
Raitano, S.
Author:
Raj, A.
Author:
Raj, D. B.T.G.
Author:
Raj, K.
Author:
Raj, Soosay T.
Author:
Raje, N.

IMPACT OF AGE ON EFFICACY AND SAFETY OF DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (D-RD) IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): MAIA: PF592

Hulin, C.; Facon, T.; Kumar, S.; More

HemaSphere. 3:248-249, June 2019.

Author:
Rajegowda, C.
Author:
Rajeh, M. N. MD

PHASE II STUDY OF ORAL RIGOSERTIB COMBINED WITH AZACITIDINE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS): S839

Navada, S. C.; Garcia-Manero, G.; Atallah, E.; More

HemaSphere. 3:373-374, June 2019.

Author:
Rajic, J.
Author:
Rajic, N.
Author:
Rajkovic, I.
Author:
Rajkumar, S.

QUALITY OF LIFE IN PATIENTS UNDERGOING CHIMERIC ANTIGEN RECEPTOR (CAR) - T CELL THERAPY VS. AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANT FOR HEMATOLOGIC MALIGNANCIES: PS1501

Sidana, S.; Dueck, A.; Burtis, M.; More

HemaSphere. 3:691-692, June 2019.

Author:
Rajkumar, S. V.

OUTCOMES OF PATIENTS WITH T(11;14) MULTIPLE MYELOMA: AN INTERNATIONAL MYELOMA WORKING GROUP MULTICENTER STUDY: PF564

Kumar, S.; Goldschmidt, H.; Mateos, M.-V.; More

HemaSphere. 3:234-235, June 2019.

HEALTH-RELATED QUALITY OF LIFE (HRQOL) OUTCOMES OF ORAL IXAZOMIB MAINTENANCE THERAPY POST AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) FROM TOURMALINE-MM3: PF626

Schjesvold, F.; Goldschmidt, H.; Maisnar, V.; More

HemaSphere. 3:266-267, June 2019.

A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF ISATUXIMAB, POMALIDOMIDE, AND LOW-DOSE DEXAMETHASONE VS POMALIDOMIDE AND LOW-DOSE DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): S824

Attal, M.; Richardson, P. G.; Rajkumar, S. V.; More

HemaSphere. 3:365, June 2019.

UPDATED RISK STRATIFICATION MODEL FOR SMOLDERING MULTIPLE MYELOMA (SMM) INCORPORATING THE REVISED IMWG DIAGNOSTIC CRITERIA: PS1349

Mateos, M.-V.; Kumar, S.; Gonzalez, V.; More

HemaSphere. 3:616, June 2019.

DEEPENING RESPONSES SEEN WITH IXAZOMIB MAINTENANCE POST-AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) ARE ASSOCIATED WITH PROLONGED PROGRESSION-FREE SURVIVAL - ANALYSIS FROM THE TOURMALINE-MM3 STUDY: PS1382

Goldschmidt, H.; Dimopoulos, M. A.; Rajkumar, S. V.; More

HemaSphere. 3:632-633, June 2019.

Author:
Rajkumar, V.
Show: